A First in Human Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Target Engagement of Single and Multiple Oral Administrations of NNC0705-0001 in Healthy Adults
Latest Information Update: 06 Jul 2025
At a glance
- Drugs NNC-0705-0001 (Primary)
- Indications Renal failure
- Focus Adverse reactions; First in man; Pharmacokinetics
- Sponsors Novo Nordisk
Most Recent Events
- 26 Jun 2025 New trial record